Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol IFI44L contributors: mct - updated : 13-03-2023
HGNC name interferon-induced protein 44-like
HGNC id 17817
EXPRESSION
Type
   expressed in (based on citations)
organ(s)
tissue
SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
Connectivebone   
cells
SystemCellPubmedSpeciesStageRna symbol
Skeletonosteoblast
cell lineage
cell lines
fluid/secretion
at STAGE
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
a ATP/GTP-binding site motif A (P-loop) domain
HOMOLOGY
Homologene
FAMILY
CATEGORY tumor suppressor
SUBCELLULAR LOCALIZATION     intracellular
intracellular,cytoplasm
basic FUNCTION
  • expression of IFI44L was increased in viral patients and FAM89A was increased in bacterial patients relative to healthy children
  • role of IFI44L in the antiviral innate immune response
  • involved in innate immune processes and act as a tumor suppressor in several cancers
  • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism
    signaling
    a component
    INTERACTION
    DNA
    RNA
    small molecule nucleotide,
    ATP/GTP
    protein
  • STAT3 regulated IFI44L expression and interacted with TET2 which induced DNA demethylation of IFI44L promoter
  • cell & other
    REGULATION
    induced by induced by IFN and HIV-1 infection
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    constitutional     --over  
    in systemic lupus erythematosus (SLE) monocyte
    constitutional     --over  
    by IFI44L promoter demethylation from whole peripheral blood in Iranian SLE patients(methylation significantly lower than healthy controls)
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
  • biomarker for non-small cell lung cancer patients
  • significant hypomethylation of two CpG sites within IFI44L promoter, was identified in patients with SLE
  • Therapy target
    SystemTypeDisorderPubmed
    immunologyautoimmuneLupus
    IFI44L is expected to become a new target for treatment of SLE
    ANIMAL & CELL MODELS